Acacia Research: A Patient Book vs. an Impatient Tape

Q2 shows a disciplined capital allocator compounding quietly — but the stock still trades at a discount to net asset value.

ACTG · Earnings Call · 2026-08-05

A Diversified Engine Firing on Most Cylinders

Acacia Research's Q2 2026 report was a study in quiet consistency. Across the board, the operating businesses delivered: Benchmark logged another record revenue quarter with $20.5M in revenue, $9.8M adjusted EBITDA, and $6.5M of free cash flow; Deflecto's restructuring is gaining traction, posting $27.1M in revenue and $1.1M adjusted EBITDA despite a soft end market; and Printronix kept grinding out cash generation at $6M revenue with $1M adjusted EBITDA. The licensing activity in the Intellectual Property segment was the real kicker, with roughly $60.6M in revenue — a reminder that this business is inherently episodic but can still pack a punch. MJ McNulty's opening remarks captured the tone: “Our results reflected continued execution across our operating businesses, disciplined capital allocation and the benefits of our diversified business model.” — Martin McNulty · 2026-08-05 The company's overall balance sheet remains a fortress — $334.6M in cash, securities, and loans receivable with no parent-company debt. But the market's reaction (or lack thereof) tells a different story. ACTG is down about 8% over the last 90 days and trades at roughly $5.71 per share of book value while the stock price hovers around $5. It's a classic value trap versus a value creation narrative, and the market seems to be waiting for a bigger catalyst than “steady execution.”

The Fine Print: IP Cash Timing and a Legacy Write-Down

The Intellectual Property platform had a strong quarter, but the headline Wi-Fi 6 portfolio settlement deserves a closer look. Management was explicit that the reported adjusted EBITDA of $10.9M for the segment is not the same as cash retained — a large portion goes to contingency fee counsel and partners under the Wi-Fi 6 arrangement. In response to a direct question, MJ McNulty said: “EBITDA is not the best proxy for that particular deal” — Martin McNulty · 2026-08-05 and clarified the cash timing: “The cash for the settlement was received in Q3, but it's booked as AR at the end of Q2.” — Martin McNulty · 2026-08-05 So the liquidity is on its way, but it wasn't in the quarter-end cash number. The Intellectual Property platform also absorbed a $3.7M nonrecurring expense tied to a legacy litigation matter that management believes is “substantially complete” and could still yield a recovery. Meanwhile, the MalinJ1 investment was written down to zero after Mycovia's liquidity issues — a full impairment that reduced book value by roughly $10M, offset partially by gains in the public portfolio. This is the flip side of the diversified model: not every bet pays off, but the company has the balance sheet to absorb it.

Our objective has never been to maximize short-term earnings. Instead, we focus on compounding long-term intrinsic value per share through disciplined capital allocation.
Martin McNulty · 2026-08-05

Valuation: The Book Says One Thing, the Tape Says Another

At the end of Q2, book value stood at $557M, or $5.71 per share, against a stock price around $5.00 — a ~12% discount. The fundamentals support the idea that the company is building real intrinsic value, but the income statement is noisy. Total Revenue swung from $124M in Q1 2026 to $54M in the most recent quarter, almost entirely due to the absence of a huge licensing settlement. Adjusted net income of $0.13/share is small relative to the asset base, and Net Income was essentially breakeven on a GAAP basis. More tellingly, the company's leverage remains minimal — Liabilities to Assets sits at 25%, and management is intent on keeping it that way. That conservative posture, combined with a steady deal flow across private equity and private credit, positions the company to be a patient buyer rather than a forced one. Investors have been pressing for a buyback for several quarters, and management has repeatedly cited tax attribute constraints. On the last call (May 2026), MJ McNulty answered the recurring question with characteristic restraint: “We evaluate the buyback in the context of other capital allocation opportunities.” — Brett Reiss, Analyst · 2026-05-07 That discomfort with a passive buyback is consistent with his longer-term view — in Q1 2026 he explained the hedging posture at Benchmark: “We are fully hedged for 2026.” — Martin McNulty, Chief Executive Officer (CEO) · 2026-03-11 That kind of de-risking is exactly what a value building block is supposed to do.

What Could Move the Needle

Acacia's own keyword trajectory shows a shift toward themes like "licensing activity" and "deal flow" in the most recent quarter — a reflection that the market is more interested in the next catalyst than the current earnings. The Wi-Fi 6 settlement and the potential resolution of the legacy litigation matter are meaningful upside drivers, but timing is uncertain. On the life sciences side, AMO Pharma's regulatory progress is a potential overhang but not yet monetizable. The real test is whether Acacia can deploy its balance sheet into an acquisition that changes the narrative from “holding company at a discount” to “operating company with momentum.” The pipeline is active, and management has shown it can execute operationally. Until then, ACTG looks like a patient compounder — but one that needs a catalyst to close the value gap.